瑞巴派特与硫糖铝对慢性非萎缩性胃炎的临床疗效及胃黏膜保护作用对比研究

目的比较瑞巴派特与硫酸铝对慢性非萎缩性胃炎的临床疗效。方法将2011年3月至2013年3月荆州市沙市区人民医院收治的97例慢性非萎缩性胃炎患者。按照随机数字法分为两组:观察组49例口服瑞巴派特,对照组48例口服硫糖铝。治疗8周后对比两组患者疗效、临床症状改善情况以及胃黏膜部位丙二醛(MDA)和前列腺素E2(PGE2)的水平。结果治疗后观察组总有效率为95.92%,对照组为87.50%,观察组显著高于对照组,两组间相比差异有统计学意义(χ2=4.663,P<0.05);观察组反酸/胃灼热、上腹疼痛缓解率显著高于对照组(P<0.05)。治疗后两组患者胃黏膜炎症积分、胃黏膜炎症病理积分均显著降低,与治疗前相比差异有统计学意义(P<0.05);其中观察组积分降低程度显著优于对照组(P<0.05);治疗后两组患者胃黏膜MDA水平显著降低,PGE2水平显著上升,与治疗前相比差异有统计学意义(P<0.05);其中观察组MDA和PGE2水平显著优于对照组(P<0.05)。结论瑞巴派特能够显著改善慢性非萎缩性胃炎患者的临床症状,疗效确切,值得临床推广。

Comparison of the Clinical Effect and Protective Effect of Gastric Mucosa of Rebamipide with Sucralfate in the Treatment of Chronic Non-atrophic Gastritis

Objective To compare the clinical efficacy of rebamipide with sucralfate in the treatment of chronic non-atrophic gastritis. Methods A total of 97 cases of chronic non-atrophic gastritis treated in Shashi District People＇s Hospital of Jingzhou City from Mar. 2011 to Mar. 2013 were divided into observation group of 49 cases and control group of 48 cases according to random-number table method. The observation group was given oral rebamipide,while the control group was treated with sucralfate. After 8 weeks of treatment,the clinical symptoms and gastric mucosal sites（ MDA） and prostaglandin E2（ PGE2）content of the two groups were compared. Results After treatment the total effective rate of the observation group was 95. 92%,of the control group was 87. 50%,the difference was statistically significant（ χ2= 4. 663,P〈0. 05）; the heartburn,acid reflux / abdominal pain remission rate of the observation group were significantly higher than the control group（ P〈0. 05）. The gastric mucosal inflammation,the inflammation of gastric mucosa pathological integral of both groupswere significantly reduced after treatment,with statistically significant difference from before treatment（ P〈0. 05）; and the observation group integral decrease was significantly better than the control group（ P〈0. 05）; the gastric mucosal MDA content of both groups decreased significantly after treatment,the content of PGE2 increased significantly,the difference was statistically significant compared with before treatment（ P〈0. 05）; the observation group＇s MDA and PGE2 changes were significantly better than the control group＇ s（ P〈0. 05）. Conclusion Rebamipide can significantly improve the clinical symptoms of patients with chronic non-atrophic gastritis,thus is worth of clinical promotion.